Clinical trials: Drug Hypersensitivity
Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
The purpose of this study is to characterize the effect of repeated oral administration of TAK-788 160 milligram (mg) once daily on the single oral and intravenous dose pharmacokinetics (PK) of midazolam.
- Trial name
- NCT04051827
- Testing
- Midazolam, TAK-788
- Where
- 8 sites in Australia, Netherlands and 1 more
- Volunteers
- 26 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Eosinophilic Esophagitis
A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
Study CC-93538-EE-001 is a Phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled induction and maintenance study to evaluate the efficacy and safety of CC- 93538 in adult and adolescent participants…
- Trial name
- NCT04753697
- Testing
- CC-93538
- Where
- 212 sites in United States, Argentina and 13 more
- Volunteers
- 430 people
- Sponsor
- Celgene
Hypersensitivity
Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis
Seasonal allergic conjunctivitis (SAC) is an irritating eye condition that affects many people, caused by hypersensitivity to normally harmless substances such as pollen, and often accompanies seasonal hay fever.
- Trial name
- NCT01569191
- Testing
- Artificial Tear Supplement, Cold compress, Anti-allergic Medication
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Aston University
Asthma
A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma
The goal of this study is to assess and compare the safety and tolerability of salbutamol administered via metered dose inhaler (MDI) containing propellant 1,1-difluoroethane (HFA-152a) or 1,1,1,2-tetrafluoroethane (HFA-134a) in…
- Trial name
- NCT06261957
- Testing
- Salbutamol HFA-134a, Salbutamol HFA-152a
- Where
- 102 sites in United States, Argentina and 11 more
- Volunteers
- 471 people
- Sponsor
- GlaxoSmithKline
Asthma
A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Low-Dose ICS Therapy.
This study is designed to determine if the investigational drug is effective and safe in individuals with asthma.
- Trial name
- NCT00603278
- Testing
- GW685698X
- Where
- 155 sites in United States, Canada and 11 more
- Volunteers
- 622 people
- Sponsor
- GlaxoSmithKline
Hymenoptera Venom Allergy, Antihypertensive Treatment
The Effect of Antihypertensive Drugs on Severity of Anaphylaxis and Side-effects During Venom Immunotherapy
There is an ongoing debate whether antihypertensive treatment with beta-blockers and/or angiotensin converting Enzyme (ACE)-inhibitors comprises a risk factor for more severe and more frequent side-effects during venom…
- Trial name
- EADOAS (NCT04269629)
- Testing
- Insect Venom
- Where
- Austria
- Volunteers
- 1,425 people
- Sponsor
- Medical University of Graz
Castration-Sensitive Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8
Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)
This phase II trial examines antiandrogen therapy interruptions in patients with hormone-sensitive prostate cancer that has spread to other places in the body (metastatic) responding exceptionally well to androgen…
- Trial name
- A-DREAM (NCT05241860)
- Testing
- Pharmacotherapy Discontinuation, Follow-Up, Questionnaire Administration
- Where
- 326 sites in United States
- Volunteers
- 79 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Pulmonary Tuberculosis
Assessing PA-824 for Tuberculosis (the APT Trial)
Assess the mycobactericidal activity of PA-824 (given at 200 mg daily) when added to first-line tuberculosis (TB) treatment (isoniazid, pyrazinamide, and a rifamycin antibiotic) over 12 weeks of treatment.
- Trial name
- NCT02256696
- Testing
- PA-824, Rifampin, Rifabutin
- Where
- South Africa
- Volunteers
- 157 people
- Sponsor
- Johns Hopkins University
Heart Diseases, Coronary Disease
CES1 Carriers in the PAPI Study
This study builds, in part, upon preliminary results generated as part of the Pharmacogenomics Anti-Platelet Intervention (PAPI) Study (NCT00799396).
- Conditions
- Heart Diseases, Coronary Disease, Coronary Artery Disease, Cardiovascular Diseases
- Trial name
- NCT03188705
- Testing
- Clopidogrel, Aspirin
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Dentinal Hypersensitivity
Research on Oral Tolerability and Product Application/Response of Two Oxalate Products for Dental Patients With Risk of Dentinal Hypersensitivity
This study will assess the oral tolerability and immediate post-treatment safety of topical application for two marketed oxalate products as initial care in dental patients to treat or prevent tooth sensitivity pain that may be…
- Trial name
- NCT02613117
- Testing
- Potassium Oxalate Gel, Potassium Oxalate Liquid, Stannous fluoride paste
- Where
- United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Procter and Gamble
Rhinitis, Allergic, Seasonal
A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis
This study compared the safety and efficacy of a generic fluticasone furoate (Lek Pharmaceuticals) nasal spray to the reference listed drug in the treatment of seasonal allergic rhinitis.
- Trial name
- NCT01279057
- Testing
- Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals), Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray
- Where
- 7 sites in United States
- Volunteers
- 727 people
- Sponsor
- Sandoz
Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome
Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis
To test the ability of palifermin (a recombinant human keratinocyte growth factor) to decrease mucocutaneous injury and to promote epithelial repair in Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome-Toxic Epidermal…
- Trial name
- NCT02037347
- Testing
- Palifermin
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Brett King
Asthma
A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Non-steroidal Therapy.
This study is designed to determine if the investigational drug is effective and safe in individuals with asthma.
- Trial name
- NCT00603382
- Testing
- GW685698X
- Where
- 149 sites in United States, Bulgaria and 12 more
- Volunteers
- 599 people
- Sponsor
- GlaxoSmithKline
Asthma, Patient Compliance
Using Information Technology to Improve Asthma Adherence
The purpose of this study is to determine whether providing patient medication adherence information on inhaled corticosteroid use to clinicians will result in improved patient adherence and asthma control.
- Trial name
- AFFIRM (NCT00459368)
- Testing
- Feedback of patient adherence information, Active control group
- Where
- United States
- Volunteers
- 2,698 people
- Sponsor
- Henry Ford Health System
Sarcoidosis, Pulmonary
Atorvastatin to Treat Pulmonary Sarcoidosis
This study will determine if atorvastatin (Lipitor) can help patients with pulmonary (lung) sarcoidosis and replace or reduce the need for patients to take steroids, such as prednisone.
- Trial name
- NCT00279708
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hand-foot Syndrome
Study of Pyridoxine for Hand-Foot Syndrome
Although pyridoxine has been used empirically for the prevention of capecitabine associated hand-foot syndrome (HFS), its efficacy needs to be demonstrated in prospective controlled trials.
- Trial name
- NCT00446147
- Testing
- Pyridoxine
- Volunteers
- 389 people, healthy volunteers welcome
- Sponsor
- Asan Medical Center
Drug Hypersensitivity
Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug Reactions
Severe skin adverse drug reactions can result in death. Toxic epidermal necrolysis (TEN) has the highest mortality (30-35%); Stevens-Johnson syndrome and transitional forms correspond to the same syndrome, but with less extensive…
- Trial name
- NCT01276314
- Testing
- anti- TNF-a, Prednisolone
- Where
- Taiwan
- Volunteers
- 135 people
- Sponsor
- Chang Gung Memorial Hospital
Eosinophilic Esophagitis, Connective Tissue Disorders
Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD
The purpose of this research study is to test the safety of losartan potassium and see what effects (good and bad) it has on you and your eosinophilic esophagitis.
- Trial name
- NCT01808196
- Testing
- Losartan Potassium
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Dentine Hypersensitivity, Dental Pain
Dose Response of a Tubule Occlusion Agent
To evaluate the efficacy of two different concentrations of a tubule occlusion agent - calcium sodium phosphosilicate in treatment of dentine hypersensitivity
- Trial name
- NCT01075256
- Testing
- 5% calcium sodium phosphosilicate toothpaste, 7.5% calcium sodium phosphosilicate toothpaste
- Where
- United States
- Volunteers
- 195 people
- Sponsor
- GlaxoSmithKline
Pulmonary Tuberculosis
Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002)
The purpose of this study is to assess the mycobactericidal activity of the moxifloxacin plus PA-824 plus pyrazinamide regimen after 8 weeks of treatment.
- Trial name
- NCT01498419
- Testing
- Moxifloxacin (M), Pretomid (Pa), Pyrazinamide (Z)
- Where
- 8 sites in South Africa, Tanzania
- Volunteers
- 207 people
- Sponsor
- Global Alliance for TB Drug Development